title: [Differentiation potential of CD41⁺ cells derived from the mouse aorta-gonad-mesonephros region, yolk sac and embryonic circulating blood].
abstract: OBJECTIVE
  To compare the differentiation ability difference of hematopoietic, mesenchymal and endothelial potential between CD41⁺ cells derived from the mouse aorta-gonadmesonephros (AGM) region, yolk sac (YS) and embryonic circulating blood (CB).
  
  
  METHODS
  CD41⁺ cells were sorted from AGM, YS and CB. The CD45 and c-kit expression were studied in CD41⁺ cells by flow cytometry. IL-3 and bone morphogenetic protein 4 (BMP-4) treatment together with semi solid culture were used to assess hematopoietic potential difference of CD41⁺ cells. Immunofluorescence staining of α-SMA was used to assess mesenchymal potential difference. The endothelial cell induction system was used to assess endothelial potential difference.
  
  
  RESULTS
  The proportions of CD45+ cells in CD41⁺ population were 51.9% (AGM), 45.8% (YS) and 22.2% (CB), respectively, while those of c-kit⁺ cells were 40.0% (AGM), 39.6% (YS) and 36.2% (CB), respectively. After stimulated by IL-3 factor, the number of total colonies increased in all three groups-derived CD41⁺ cells compared to that of unstimulated group[(14.1±1.9) vs (1.2±0.2), (32.4±1.1) vs (18.4±2.2) and (41.8±0.9) vs (10.4±1.8)], (P<0.01). After stimulated by BMP-4 factor, compared to unstimulated group, CFU-Mix colony number in CD41⁺ cells from AGM region and YS were significantly decreased[(0.5±0.6) vs (3.2±0.8), (1.3±0.7) vs (7.4±1.7)](P<0.01), but there was no difference in CB group[(2.5±0.5) vs (3.9±1.5)](P>0.01). The mesenchymal marker α-SMA was highly expressed in CD41⁺ cells from AGM region and YS, but lowly expressed in CD41⁺ cells from CB.
  
  
  CONCLUSIONS
  There are some differences between CD41⁺ cells in AGM region, YS and CB on hematopoietic cell surface marker expression, hematopoietic colony formation with IL-3 and BMP-4 stimulation.
authors.affiliation: Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
authors.forename: Si-ting
authors.initials: ST
authors.lastname: Li
authors.forename: Jun-nian
authors.initials: JN
authors.lastname: Zhou
authors.forename: Hai-xun
authors.initials: HX
authors.lastname: Chen
authors.forename: Yi-fan
authors.initials: YF
authors.lastname: Xie
authors.forename: Wen-yan
authors.initials: WY
authors.lastname: He
authors.forename: Xue
authors.initials: X
authors.lastname: Nan
authors.forename: Wen
authors.initials: W
authors.lastname: Yue
authors.forename: Bing
authors.initials: B
authors.lastname: Liu
authors.forename: Xue-tao
authors.initials: XT
authors.lastname: Pei
mesh_terms: D000818:Animals; D001011:Aorta / Q000166:cytology*; D055415:Bone Morphogenetic Protein 4 / Q000494:pharmacology; D002454:Cell Differentiation; D006066:Gonads / Q000166:cytology*; D007377:Interleukin-3 / Q000494:pharmacology; D008650:Mesonephros / Q000166:cytology*; D051379:Mice; D040201:Platelet Membrane Glycoprotein IIb / Q000378:metabolism; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D015017:Yolk Sac / Q000166:cytology*
chemical_list: D055415:Bone Morphogenetic Protein 4; D007377:Interleukin-3; D040201:Platelet Membrane Glycoprotein IIb; D019009:Proto-Oncogene Proteins c-kit